Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 28 Publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M2nHO2Z2dmO2aX;uJGF{e2G7 M2PmcFAvPcLizszN NFfaRmEzPCCq MVT3ZZRmeg>? MmT1cY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> Ml;6NlUyOjNyOEK=
Eca109 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrHNE42NzJwNT:1JO69VQ>? NUPJVZNiOjRxNEivO|IhcA>? NX;WN2NNf2G2ZYK= Mkn0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= NUjSSmE2OjVzMkOwPFI>
Eca109 MUXGeY5kfGmxbjDBd5NigQ>? M4\adVAvPcLizszN NEG5Wng3NzF{L{K0JIg> NHzSUXd4[XSnch?= NFjh[m9qdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg M3LJS|I2OTJ|MEiy
Eca109 NEjuVYtHfW6ldHnvckBCe3OjeR?= NH70cFgxNjYEoN88US=> MVeyOEBp NFTBUGN4[XSnch?= NHnhZoJqdmirYnn0d{Bk\WyuIHnueoF{cW:w Mn;zNlUyOjNyOEK=
Eca109 NHTVO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSwMlXDqM7:TR?= M1PRZ|I1KGh? M1zOTZdifGW{ NVrucYticW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? NIC5XZIzPTF{M{C4Ni=>
Eca109 NYm0U4xITnWwY4Tpc44hSXO|YYm= M4rzVVAvPS9zIN88US=> M36xXVI1KGh? MlfIe4F1\XJ? NGrFbHZl\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{ NHH1dWkzPTF{M{C4Ni=>
SW1116  NILle2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\ITFQxNjVxMT:yM|Uh|ryP MUm0PEBp MmfuSG1UVw>? M1LxWYVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> Mn;INlQ5PzR{OE[=
LOVO MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYiwMlUwOS9{L{Wg{txO M2\kO|Q5KGh? NWO0U2JETE2VTx?= MXjlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u MkDjNlQ5PzR{OE[=
SW1116  NHK5bHRHfW6ldHnvckBCe3OjeR?= NWCyOWplOTBizszN NY\0PGtMPDhiaB?= NHPOUopFVVOR NUeyVXRKcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk NH3lNpgzPDh5NEK4Oi=>
LOVO NHL4U4lHfW6ldHnvckBCe3OjeR?= M1HV[VExKM7:TR?= M2\LclQ5KGh? M1zENmROW09? NHTZN5dqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? NFzlXWszPDh5NEK4Oi=>
SW1116  M2HJVGFxd3C2b4Ppd{BCe3OjeR?= NF\yRnEyOCEQvF2= M3TXN|Q5KGh? NYL6XXlYTE2VTx?= NWjVdHhj\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ M{XDZlI1QDd2Mki2
LOVO M2\qeGFxd3C2b4Ppd{BCe3OjeR?= MWmxNEDPxE1? NUOzfmp1PDhiaB?= MlK0SG1UVw>? NFL3fYhmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> NGXufVQzPDh5NEK4Oi=>
RPMI-8226 M{ftWmFxd3C2b4Ppd{BCe3OjeR?= MXuxM|Ih|ryP MUG0PE84Oi97NjDo M{HrV2ROW09? MYjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MmXNNlQ5OzNzMEi=
OPM-2  NWGxRmRySXCxcITvd4l{KEG|c3H5 MUOxM|Ih|ryP M1jIWVczNzl4L{GyNEBp MYjEUXNQ NIX2d2hqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NUjHfoZOOjR6M{OxNFg>
JJN3  MULBdI9xfG:|aYOgRZN{[Xl? M{H1NFAvPS9zIN88US=> NUm5Sll{OjRxNEigbC=> NGL0TYxFVVOR NYXoeot6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NULiSoVPOjR6M{OxNFg>
NCI-H929  MYPBdI9xfG:|aYOgRZN{[Xl? M4TVVlEwOiEQvF2= NYnxTWU4PzJxOU[vNVIxKGh? MYPEUXNQ MUjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVmyOFg{OzFyOB?=
RPMI-8226 MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTvTJEyNzJizszN M1rsZ|I1NzR6L{eyJIg> M3[3NmROW09? NV\6WnUz[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MlL1NlQ5OzNzMEi=
OPM-2  NF;OWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjo[VQyNzJizszN MX[yOE81QC95MjDo M1P3NmROW09? M323XIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MV2yOFg{OzFyOB?=
JJN3  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O1c|AvPS9zIN88US=> NFTQVpczPC92OD:3NkBp NGHEZoFFVVOR MWPh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MXeyOFg{OzFyOB?=
NCI-H929  MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\oblEwOiEQvF2= NXTaRWFHOjRxNEivO|IhcA>? MVXEUXNQ M4TWSYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 Mn3VNlQ5OzNzMEi=
HeLa NV3SZXRIU2mwYYPlJGF{e2G7 M1i3fGtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> MmXCNlQ4QDByOUi=
HeLa NVvuSlkxU2mwYYPlJGF{e2G7 NXKwOYZHU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz MUOyOFc5ODB7OB?=
HeLa MVPLbY5ie2ViQYPzZZk> NVftcWVzU2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? NGG1SpUzPDd6MEC5PC=>
HeLa NYD5ZppXU2mwYYPlJGF{e2G7 M1ruTWtqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> NGHWd20zPDd6MEC5PC=>
NB4 M1TWT2Z2dmO2aX;uJGF{e2G7 NVy3[FlwOi53L{WvO{42NzFyIN88US=> MWSyOEBp MYjEUXNQ MVnpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh NYPYcJdIOjR2OES4O|A>
CD4+ CD25− T  M4XQdmZ2dmO2aX;uJGF{e2G7 M2jrN|EwPSEQvF2= M1fTdpJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? NInUTJUzPDR5NkO2NC=>
BV-173 NHzFPGhCeG:ydH;zbZMhSXO|YYm= MljyNE4zPS9yLkWvNE44PS9zIN88US=> MnHvOFgwPzJxOU[gbC=> NYH2RYU5yqCSQmO= MmG2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MoLiNlQ1OjN4MUO=
ML-1 MknVRZBweHSxc3nzJGF{e2G7 Ml7zNE4zPS9yLkWvNE44PS9zIN88US=> NV;1UpZlPDhxN{KvPVYhcA>? NFP2c27DqFCEUx?= MXfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NUfjWFZkOjR2MkO2NVM>
HL-60 MX7BdI9xfG:|aYOgRZN{[Xl? NEm3bHIxNjJ3L{CuOU8xNjd3L{Gg{txO NF\sdJM1QC95Mj:5OkBp NUPmdYdCyqCSQmO= M{fEOIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NYHDXplyOjR2MkO2NVM>
KG-1a NEfafmpCeG:ydH;zbZMhSXO|YYm= NFjaW2kxNjJ3L{CuOU8xNjd3L{Gg{txO NVXSXXNLPDhxN{KvPVYhcA>? NWPYdmp5yqCSQmO= NF3R[YtqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NHfqeI4zPDR{M{[xNy=>
BV-173 NYTNN2EzTnWwY4Tpc44hSXO|YYm= M37UUFI2OC93MEDuUS=> MoLxOFghcA>? Mn\pxsBRSlN? MmXTbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MXSyOFQzOzZzMx?=
CEM MnXjSpVv[3Srb36gRZN{[Xl? NGfHUW0zPTBxNUCwcm0> MorSOFghcA>? NVrwfVdnyqCSQmO= M2fKd4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MY[yOFQzOzZzMx?=
HL-60 NIWxNFFHfW6ldHnvckBCe3OjeR?= NVzz[VFFOjVyL{WwNI5O MUO0PEBp NVjwO205yqCSQmO= NX63c2R3cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NYnkNlVMOjR2MkO2NVM>
ML-1 M{\wWGZ2dmO2aX;uJGF{e2G7 MVWyOVAwPTBybl2= M4HnZlQ5KGh? MWlCpHBDWw>? NELL[oVqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= MmjzNlQ1OjN4MUO=
DLD-1 MkDxSpVv[3Srb36gRZN{[Xl? NUi3SoduOjVyL{WwNI5O NYO1NFRXPDhiaB?= M3\oc:KhWEKV MUXkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NVjXdVdJOjR2MkO2NVM>
HCT-116 NHzrVYhHfW6ldHnvckBCe3OjeR?= NXjqXXpROjVyL{WwNI5O MYW0PEBp NIj6d47DqFCEUx?= NYXxcVVr\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NUnUUm9oOjR2MkO2NVM>
U937-A/E-9/14/18  NUfzeZd4SXCxcITvd4l{KEG|c3H5 MVewMlAyNzBwMT:xM|ExKM7:TR?= NGfxSpE1QCCq Ml\JbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIjPRoMzPDNyMES1Oi=>
HT29 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPkZ2RxPzJiaB?= M13SVmlEPTB;MUSwNOKyOTd7IN88US=> MVKyOFE4OjB4MR?=
SW48 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi3VGM4OiCq MXTJR|UxRTF3LkNCtVYvOiEQvF2= NVHk[YVVOjRzN{KwOlE>
HCT116 NFPMSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYi3NkBp MoT3TWM2OD1zLkhCtVAvPCEQvF2= NHHBU20zPDF5MkC2NS=>
HepG2 M2fPXmZ2dmO2aX;uJGF{e2G7 Mm\ONE42NzFizszN NH3iSoczPCCq NV7CVVdOTE2VTx?= NHO4NpB2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MYOyOFE1Pjh5NB?=
LS174T NIHwSJRHfW6ldHnvckBCe3OjeR?= MkjQNE42NzFizszN NY\SUHFOOjRiaB?= NVz3ToZKTE2VTx?= NHjnOW1t\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> NH:xe3AzPDF2Nki3OC=>
HepG2 NUXKbVdvSXCxcITvd4l{KEG|c3H5 MXKxM|ExNzFyMDFOwG0> MW[3JIQ> MWHEUXNQ M3rFZolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX;pbnlbOjRzNE[4O|Q>
LS174T MoXiRZBweHSxc3nzJGF{e2G7 NUTucWZUOS9zMD:xNFAh|ryP NXfxW2hiPyCm Mn7aSG1UVw>? NIi5UpFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFnWcFQzPDF2Nki3OC=>
QBC-939 M4[2[2Fxd3C2b4Ppd{BCe3OjeR?= M33kPVEwOTBxMUCwJO69VQ>? M1HWc|ch\A>? MXHEUXNQ MoLkbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlrlNlQyPDZ6N{S=
U251 Mk\lRZBweHSxc3nzJGF{e2G7 M3L4bFEwOTBxMUCwJO69VQ>? NF[4XFA4KGR? MVXEUXNQ NYXoVpY5cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{[xN|I1OTR4OEe0
HL-60 NGnYUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6xJO69VQ>? M3jQNlQ5KGh? NVPteGFrcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= MUCyOFAxODN{NB?=
MDA‑MB‑453 NYDifJR2TnWwY4Tpc44hSXO|YYm= MoHvNE4zNzFizszN NELZdXM4OiCq MV;jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= Mk\BNlM5PDR{Mki=
HCC1569 NYi2No1UTnWwY4Tpc44hSXO|YYm= MUWwMlIwOSEQvF2= NITkb4k4OiCq NIPr[otk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NHHUcIQzOzh2NEKyPC=>
BT‑474 MXfGeY5kfGmxbjDBd5NigQ>? NV;0WnZVOC5{L{Gg{txO NETQXnU4OiCq MmH4Z4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NUTEd5I4OjN6NESyNlg>
AGS NXW0cY1JSXCxcITvd4l{KEG|c3H5 M3S0V|UwOTBxMkCvOVAh|ryP NGrvfW01QMLiaNMg MYLEUXNQ MVTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> MmnTNlM2QDJ5OES=
A549 NXu0NY1ESXCxcITvd4l{KEG|c3H5 NWXqbGJmPS9zMD:yNE82OCEQvF2= M2LXXFQ5yqCqwrC= NIHG[m1FVVOR NE\iXYhqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? MnHoNlM2QDJ5OES=
AGS  NWTad|RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m3WlUwOTBxMkCvOVAh|ryP NIn1R241QMLiaNMg NVX6b4w3TE2VTx?= MmXybY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg M2jCPFI{PTh{N{i0
Kasumi-1 M4\reGFxd3C2b4Ppd{BCe3OjeR?= NH\KRnIxNjVizszN NUHiTYh2PDkEoHlCpC=> MmW2[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NGDiPZIzOzR7M{O0PC=>
OCI-AML3 NYXvN5JOSXCxcITvd4l{KEG|c3H5 M4roRVIvPSEQvF2= NYn5[ZpPPDkEoHlCpC=> NVrCfZhl\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MYeyN|Q6OzN2OB?=
MV4-11 MkD0RZBweHSxc3nzJGF{e2G7 M2n1TFIvPSEQvF2= Mn7LOFjDqGkEoB?= MnTL[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NIKxWG8zOzR7M{O0PC=>
NK  M1\Nb2N6fG:2b4jpeJkhSXO|YYm= NVixXWd2OC5yMj2yNEDPxE1? NV62PI1mPSCm NH71dIhl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n NUTqc|dDOjN|MkiwPFg>
NK  MV;BdI9xfG:|aYOgRZN{[Xl? M1rSR|AvODJvMkCg{txO NInjSFY2KGR? M{PiWoRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? MonuNlM{OjhyOEi=
NK  MVvGeY5kfGmxbjDBd5NigQ>? NEjUNJYxNjBzLUKwJO69VQ>? Mn[wOUBl M2HTV4NifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> M{mzRlI{OzJ6MEi4
MOLT4/DNR NEjTZVVHfW6ldHnvckBCe3OjeR?= MkXUOUDPxE1? M4fvZVQh\A>? NX3lW|dlemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? MYeyN|A3ODV5MB?=
Jurkat/DOX NG\WfVhHfW6ldHnvckBCe3OjeR?= NWHtRY5vPSEQvF2= MXq0JIQ> NHjDNW9z\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? Mm\jNlMxPjB3N{C=
MOLT4/DNR Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HaclUh|ryP M1K2OFQh\A>? Mnu3doVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NGHSZlczOzB4MEW3NC=>
Jurkat/DOX NHTyfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTJbW42KM7:TR?= MWS0JIQ> Moi3doVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= M{nHXFI{ODZyNUew
ccRCC  M33nN2Fxd3C2b4Ppd{BCe3OjeR?= NVHmXG1zOC5yMT2xNO69VQ>? M3;ONlczKGh? MWfEUXNQ MYDoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v M2fVWFIzQDJ4NE[3
TNBC  Mkf4RZBweHSxc3nzJGF{e2G7 NYfMVnkyOC5yMT2xNO69VQ>? M3jwUVczKGh? MV;EUXNQ MoPQbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MVKyNlgzPjR4Nx?=
A498 NEmwZY1CeG:ydH;zbZMhSXO|YYm= MUGwMlAyNTFyzszN MW[3NkBp MYjEUXNQ M4XK[olv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NIrCUWkzOjh{NkS2Oy=>
KIJ265T NH3jbGFCeG:ydH;zbZMhSXO|YYm= NFHpcWExNjBzLUGw{txO NVixWmVLPzJiaB?= NVr5WVF2TE2VTx?= NYP2PXpncW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MlnDNlI5OjZ2Nke=
MDA-231 M4nUTmFxd3C2b4Ppd{BCe3OjeR?= M1j0WVAvODFvMUFOwG0> NISzUYU4OiCq M4O4fmROW09? NG\pXXFqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NF34XGYzOjh{NkS2Oy=>
BT-20 M3PPb2Fxd3C2b4Ppd{BCe3OjeR?= MlGyNE4xOS1zMN88US=> NWnMVHllPzJiaB?= NWf5R2pLTE2VTx?= MX\pcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu Mn;DNlI5OjZ2Nke=
U937 M2TEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfEfFl4PS1{MDFOwG0> MmW2NlQwPDhxN{KgbC=> MV;pcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MmHLNlI4PjdyMkG=
HL60 NYPhVVRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfTOU0zOCEQvF2= Mon0NlQwPDhxN{KgbC=> NVT0fmZxcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NWf3VXJ4OjJ5NkewNlE>
U937 MnLiRZBweHSxc3nzJGF{e2G7 NX\T[YtuOTVizszN M3v4elI1NzR6L{eyJIg> NWHXbVFxcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MorlNlI4PjdyMkG=
HL60 NVfrT3VMSXCxcITvd4l{KEG|c3H5 NYXpTGtROTVizszN M4TYVFI1NzR6L{eyJIg> NV;ldFQ3cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NXjlXZFFOjJ5NkewNlE>
LS411N  NXfxSldxSXCxcITvd4l{KEG|c3H5 NHf0cnIxNjVizszN NEjrTIk4OiCq NWfHbYN3cW6lcnXhd4V{KE[jczDtVm5CKGyndnXs NUnTPWVrOjJ2NkG2PVU>
MDA-MB-231 MXLBdI9xfG:|aYOgRZN{[Xl? MUexNEDPxE1? NVroSFBtPDhiaB?= Mn3xdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXGyNVg5PzZ7Nx?=
MCF-7  NX61fFRESXCxcITvd4l{KEG|c3H5 Ml;2NVAh|ryP MVW0PEBp MX7y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NG\KWIczOTh6N{[5Oy=>
A375 M1\HZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHEPWw3OC53IN88US=> Mo\jNU82NzhiZB?= NV76fYFocW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M3ezZlIyPzl4NkKy
SKMEL1 M{jKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jwe|AvPSEQvF2= M4HUcFEwPS96IHS= Moi1bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MmiwNlE4QTZ4MkK=
SKMEL3 NVzBZlkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG3NE42KM7:TR?= NX:3OWhpOS93L{ig[C=> MnyzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MXuyNVc6PjZ{Mh?=
SKMEL28 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TjPVAvPSEQvF2= MoDrNU82NzhiZB?= M3[yOolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NInrRZUzOTd7Nk[yNi=>
MeWo Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[wdWQxNjVizszN M2DEO|EwPS96IHS= MYDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NGDIeI8zOTd7Nk[yNi=>
B16 NI\wNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjRVWgxNjVizszN MXyxM|UwQCCm M2OwfYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M1zCeVIyPzl4NkKy
Ly 1 M3\adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPJ[Xd{OjRiaB?= Ml3iTWM2OD15LkOg{txO Mm\MNlE4PzJyNEm=
Ly 7 NVfiR3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6yOEBp MVHJR|UxRTFyLkeg{txO NX\YO3ZFOjF5N{KwOFk>
Su-DHL6 M{LpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWyOEBp M1v4bGlEPTExvK6yNEDPxE1? M{foNlIyPzd{MES5
Ly 10 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;rNlQhcA>? NUizVVhnUUN3MP-8olIxKM7:TR?= M3\ST|IyPzd{MES5
RIVA M4SxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O3SVI1KGh? MlPWTWM2OO,:nkKwJO69VQ>? MVuyNVc4OjB2OR?=
Su-DHL2 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TDZ|I1KGh? M3f0XmlEPTExvK6yNEDPxE1? MYGyNVc4OjB2OR?=
Ly 1 NX:yfFUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO3OFghcA>? MYLJR|UxRTBwM{Sg{txO M2jpdVIyPzd{MES5
Ly 7 NUGxRYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHHT401QCCq NGj1U5JKSzVyPUCuNFI2KM7:TR?= Mlm5NlE4PzJyNEm=
Su-DHL6 NIPPfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXy0PEBp MYXJR|Ux97zgMkCg{txO MVWyNVc4OjB2OR?=
Ly 10 NFLTSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPx[FM1QCCq M{jSNmlEPTB;MT64JO69VQ>? MX[yNVc4OjB2OR?=
RIVA M37tNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;JelQ5KGh? MX;JR|Ux97zgMkCg{txO NE\5XJkzOTd5MkC0PS=>
Su-DHL2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rxZVQ5KGh? NWjzfY9WUUN3ME2xO{41KM7:TR?= MlLaNlE4PzJyNEm=
Ly 1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qyW|czKGh? NEC3NIlKSzVyPUCuNFEh|ryP NVzrOYUyOjF5N{KwOFk>
Ly 7 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\RcVczKGh? M{fQSmlEPTB;MD6wNVgh|ryP NXv2bmE6OjF5N{KwOFk>
Su-DHL6 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTQOopyPzJiaB?= NGTPPWRKSzVyPUGuOkDPxE1? MYWyNVc4OjB2OR?=
Ly 10 NV\IWVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVS3NkBp M{j6ZmlEPTB;MT6yJO69VQ>? MoDHNlE4PzJyNEm=
RIVA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjMUVk4OiCq MYjJR|Ux97zgMkCg{txO NYDBc5lFOjF5N{KwOFk>
Su-DHL2 NV7hZnA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH2O|IhcA>? NI\m[ZhKSzVyPUGxMlIh|ryP MkjBNlE4PzJyNEm=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Recruiting Drug: Decitabine Healthy EpiDestiny Inc. October 9 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03828084 Completed Drug: Decitabine Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals April 17 2019 Phase 1
NCT03593915 Recruiting Combination Product: Alvocidib Plus Decitabine Myelodysplastic Syndromes (MDS) Tolero Pharmaceuticals Inc. August 29 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID